“Andexxa is a strategic fit with our existing
portfolio of transformative medicines and is well-aligned with our
demonstrated expertise in hematology, neurology and critical care,” says
Alexion (NASDAQ:ALXN) CEO Ludwig Hantson.
The $18 per share all-cash deal is more than double Portola’s (NASDAQ:PTLA) close last night of $7.76. It’s set to close in Q3.
A conference call to discuss is set for 8 ET.
https://seekingalpha.com/news/3568985-alexion-buying-portola-for-18-share
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.